Interference with complement regulatory molecules as a possible therapeutic strategy in HIV infection

Bibliography

• MATHE G: Hypothetical reasons of the HIV1-AIDS `tritherapy' failure. A challenging model. Biomed. Pharmacother. (1997) 51:413–416.
   PubMed Web of Science ®Google Scholar
• IZOPET J, SALAMA G, PASQUIER C et al.: Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J. Acquir. Immune Defic. Syndr. Hum. RetroviroL (1998) 19:478–483.
   PubMedGoogle Scholar
• POMERANTZ RJ: How HIV resists eradication. Hosp. Pract. (1993) 33:87–90.
   Web of Science ®Google Scholar
• GALLO R: The world of HIV disease, some new approaches to block it. Bulletin et Memoires del Academie Royale de Medecine de Belgique (1998) 153:339–342.
   PubMedGoogle Scholar
• KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. (1998) 4:1302–1307.
   PubMed Web of Science ®Google Scholar
• BANAPOUR B, SERNATINGER J, LEVY JA: The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology (1986) 152:268–271.
   PubMed Web of Science ®Google Scholar
• EBENBICHLER CF, THIELENS NM, VORNHAGEN R,MARSCHANG P, ARLAUD GJ, DIERICH MP: Human immunodeficiency virus Type 1 activates the classical pathway of complement by direct Cl binding through specific sites in the transmembrane glycoprotein gp41. .1 Exp. Med. (1991) 174:1417–1424.
   Google Scholar
• MARSCHANG P, GURTLER L, TOTSCH M et al.: HIV-1 HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. AIDS (1993) 7:903–910.
   PubMed Web of Science ®Google Scholar
• MARSCHANG P, KRUGER U, OCHSENBAUER C et al.:Complement activation by HIV-1-infected cells: the role of transmembrane glycoprotein gp41. Acquir. Immune Defic. Syndr. Hum. Retrovirot (1997) 14:102–109.
   PubMedGoogle Scholar
• SOLDER BM, SCHULZ TF, HENGSTER P et al.: HIVHIV-infected cells differentially activate the human complement system independent of antibody. Immunol. Lett. (1989) 22:135–145.
   PubMed Web of Science ®Google Scholar
• STOIBER H, CLIVIO A, DIERICH MP: Role of complementin HIV infection. Ann. Rev. Immunol. (1997) 15:649–674.
   PubMed Web of Science ®Google Scholar
• HARADA S, YOSHIYAMA H, YAMAMOTO N: Effect of heatfresh human serum on the infectivity of human T-cell lymphotropic virus Type III evaluated with new bioassay systems. Din. Microbiology (1985) 22:908–911.
   Web of Science ®Google Scholar
• SPEAR GT, LANDAY AL, SULLIVAN BL, DITTEL B, LINT TF: Activation of complement on the surface of cells infected by human immunodeficiency virus. J. Immunol. (1990) 144:1490–1496.
   PubMed Web of Science ®Google Scholar
• DIERICH MP, FRANK I, STOIBER H et at: The envelope of HIV. Immunol. Lett. (1996) 54:205–206.
   PubMed Web of Science ®Google Scholar
• FRANK I, STOIBER H, GODAR S et at: Acquisition of host cell-surface-derived molecules by HIV-1. AIDS (1996) 10: 1611-1620.
   Google Scholar
• PINTER C, SICCARDI AG, LONGHI R, CLIVIO A: Directinteraction of complement factor H with the Cl domain of HIV Type 1 glycoprotein 120. AIDS Res. Hum. Retro viruses (1995) 11:577–588.
   PubMed Web of Science ®Google Scholar
• PINTER C, SICCARDI AG, LOPALCO L, LONGHI R, CLIVIOA: HIV glycoprotein 41 complement factor H interact with each other share functional as well as antigenic homology. AIDS Res. Hum. Retro viruses (1995) 11:971–980.
   PubMed Web of Science ®Google Scholar
• STOIBER H, PINTER C, SICCARDI AG, CLIVIO A, DIERICH MP: Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H decay accelerating factor (DAF, CD55). Exp. Med. (1996) 183:307–310.
   PubMed Web of Science ®Google Scholar
• DIERICH MP, STOIBER H, CLIVIO A: A 'complementary' AIDS vaccine. Nature Med. (1996) 2:153–155.
   PubMed Web of Science ®Google Scholar
• STOIBER H, EBENBICHLER C, SCHNEIDER R, JANATOVA J,DIERICH MP: Interaction of several complement proteins with gp120 gp41, the two envelope glycopro-teins of HIV-1. AIDS (1995) 9:19–26.
   PubMed Web of Science ®Google Scholar
• MATSUSHITA M, ENDO Y, NONAKA M, FUJITA T: Complement-mediated serine proteases in tunicates vertebrates. Cum Opin. Immunol. (1998) 10:29–35.
   PubMed Web of Science ®Google Scholar
• LEGENDRE C, GRAS G, KRZYSIEK R, GALANAUD P, RICHARD Y, DORMONT D: Mechanisms of opsonized HIV entry in normal B lymphocytes. FEBS Lett. (1996) 381:227–232.
   PubMed Web of Science ®Google Scholar
• REISINGER EC, VOGETSEDER W, BERZOW D et al.: Complement-mediated enhancement of 11IV-1 infection of the monoblastoid cell line U937. AIDS (1990) 4:961–965.
   PubMed Web of Science ®Google Scholar
• SOELDER BM, REISINGER EC, KOEFLER D, BITTERLICH G,WACHTER H, DIERICH MP: Complement receptors: another port of entry for HIV. Lancet (1989) 2:271–272.
   PubMed Web of Science ®Google Scholar
• BOYER V, DELIBRIAS C, NORAZ N, FISCHER E,KAZATCHKINE MD, DESGRANGES C: Complement receptor Type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand. J. Immunol. (1992) 36:879–883.
   PubMed Web of Science ®Google Scholar
• BOYER V, DESGRANGES C, TRABAUD MA, FISCHER E,KAZATCHKINE MD: Complement mediates human immunodeficiency virus Type 1 infection of a human T cell line in a CD4- antibody-independent fashion. J. Exp. Med. (1991) 173:1151–1158.
   PubMed Web of Science ®Google Scholar
• MARSCHANG P, SODROSKI J, WURZNER R, DIERICH MP:Decay-accelerating factor (CD55) protects human immunodeficiency virus Type 1 from inactivation by human complement. Eur.J. Immunol. (1995) 25:285–290.
   PubMed Web of Science ®Google Scholar
• ABBATE I, CAPOBIANCHI MR, FAIS S et al.: Host cellantigenic profile acquired by 11IV-1 is a marker of its cellular origin. Arch. Virol. (1995) 140:1849–1854.
   PubMed Web of Science ®Google Scholar
• SPEAR GT, SULLIVAN BL, TAKEFMAN DM, LANDAY AL,LINT TF: Human immunodeficiency virus (HIV)-infected cells free virus directly activate the classical complement pathway in rabbit, mouse guinea-pig sera; activation results in virus neutraliza-tion by virolysis. Immunol. (1991) 73:377–382.
   PubMed Web of Science ®Google Scholar
• STOIBER H, THIELENS NM, EBENBICHLER C, ARLAUD GJ,DIERICH MP: The envelope glycoprotein of HIV-1 gp120 human complement protein Clq bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of 11IV-1, share antigenic homology. Eur. J. Immunol. (1994) 24:294–300.
   PubMed Web of Science ®Google Scholar
• BLACKMORE TK, HELLWAGE J, SADLON TA et al.: Identi-fication of the second heparin-binding domain in human complement factor H. J Immunol (1998) 160:3342–3348.
   PubMed Web of Science ®Google Scholar
• BLACKMORE TK, SADLON TA, WARD HM, LUBLIN DM, GORDON DL: Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. Immunol. (1996) 157:5422–5427.
   Web of Science ®Google Scholar
• GORDON DL, KAUFMAN RM, BLACKMORE TK, KWONG J, LUBLIN DM: Identification of complement regulatory domains in human factor H. J. Immunol. (1995) 155:348–356.
   PubMed Web of Science ®Google Scholar
• HELLWAGE J, SKERKA C, ZIPFEL PF: Biochemicalfunctional characterization of the factor-H-related protein 4 (FHR-4). Immunopharmacology (1997) 38:149–157.
   PubMed Web of Science ®Google Scholar
• KOTARSKY H, HELLWAGE J, JOHNSSON E et al.: Identifi-cation of a domain in human factor H factor H-like protein-1 required for the interaction with strepto-coccal M proteins. J. Immunol. (1998) 160:3349–3354.
   PubMed Web of Science ®Google Scholar
• KUHN S, SKERKA C, ZIPFEL PF: Mapping of the comple-ment regulatory domains in the human factor H-like protein 1 in factor Hl. Immunol. (1995) 155:5663–5670.
   Web of Science ®Google Scholar
• KUHN S, ZIPFEL PF: Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 factor H. Eur. J. Immunol. (1996) 26:2383–2387.
   PubMed Web of Science ®Google Scholar
• PRODINGER WM, HELLWAGE J, SPRUTH M, DIERICH MP, ZIPFEL PF: The C-terminus of factor H: monoclonal antibodies inhibit heparin binding identify epitopes common to factor H factor H-related proteins. Biochemical]. (1998) 331:41–47.
   PubMed Web of Science ®Google Scholar
• PINTER C, STOIBER H, BELTRAMI S et al.: Peptides derived from two regions of SCR 13 inhibit the interac-tion of complement factor H with HIV and induce killing of HIV-infected cells. (Submitted).
   Google Scholar
• MCINERNEY TL, EL AHMAR W, KEMP BE, POUMBOURIOS P: Mutation-directed chemical cross-linking of Human Immunodeficiency virus Type 1 gp41 oligomers. J. Virol. (1998) 72:1523–1533.
   PubMed Web of Science ®Google Scholar